Savara (NASDAQ:SVRA) Shares Gap Down on Analyst Downgrade

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) gapped down before the market opened on Wednesday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. The stock had previously closed at $3.83, but opened at $3.67. HC Wainwright currently has a buy rating on the stock. Savara shares last traded at $3.61, with a volume of 493,595 shares.

Several other research analysts also recently commented on SVRA. JMP Securities restated a "market outperform" rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reissued an "in-line" rating and set a $5.00 price target (down previously from $7.00) on shares of Savara in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Savara has an average rating of "Moderate Buy" and a consensus target price of $10.17.

Hedge Funds Weigh In On Savara

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its holdings in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock valued at $109,000 after buying an additional 18,534 shares in the last quarter. FMR LLC boosted its stake in Savara by 9.6% in the third quarter. FMR LLC now owns 1,083,893 shares of the company's stock valued at $4,596,000 after acquiring an additional 95,154 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Savara by 9.0% in the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock valued at $191,000 after acquiring an additional 3,706 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company's stock worth $3,865,000 after purchasing an additional 642,259 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Savara during the third quarter worth $174,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Down 15.1 %

The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a fifty day moving average price of $3.96 and a 200 day moving average price of $4.22.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). Analysts forecast that Savara Inc will post -0.44 earnings per share for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.